Please use this identifier to cite or link to this item: https://doi.org/10.1111/j.1600-0404.2009.01263.x
Title: A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease
Authors: Narasimhalu, K.
Effendy, S.
Sim, C.H.
Lee, J.M.
Chen, I.
Hia, S.B.
Xue, H.L.
Corrales, M.P.
Chang, H.M.
Wong, M.C.
Chen, C.P.
Tan, E.K. 
Keywords: Cognitive impairment no dementia
Rivastigmine
Stroke
Issue Date: Apr-2010
Source: Narasimhalu, K., Effendy, S., Sim, C.H., Lee, J.M., Chen, I., Hia, S.B., Xue, H.L., Corrales, M.P., Chang, H.M., Wong, M.C., Chen, C.P., Tan, E.K. (2010-04). A randomized controlled trial of rivastigmine in patients with cognitive impairment no dementia because of cerebrovascular disease. Acta Neurologica Scandinavica 121 (4) : 217-224. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1600-0404.2009.01263.x
Abstract: Objectives - The safety and efficacy of early acetylcholinesterase inhibitors therapy in patients with cognitive impairment no dementia (CIND) after a cerebrovascular accident have not been examined. In this study, we investigated the safety and efficacy of rivastigmine in cognition, particularly executive function in patients with CIND because of cerebrovascular disease. Methods - This study was a 24-week, double-blind, randomized, placebo-controlled trial of ischemic stroke patients seen at a tertiary hospital who had cognitive impairment no dementia because of cerebrovascular disease. The intervention was either rivastigmine or placebo up to 9 mg/day. The primary outcome of interest was mean change from baseline in the Ten-Point Clock Drawing and Color Trails 1 and 2. Results - Fifty patients were randomized into rivastigmine (n = 25) and placebo (n = 25) arms. Patients in the rivastigmine group showed statistically significant improvement (1.70 vs 0.13, P = 0.02) on the animal subtask of the verbal fluency measure compared with placebo. There was also a trend (non-significant) towards improvement in Color Trails II. Conclusions - In this pilot study, we demonstrated that rivastigmine was well tolerated in patients with CIND because of cerebrovascular disease and may potentially improve executive functioning. © 2009 Blackwell Munksgaard.
Source Title: Acta Neurologica Scandinavica
URI: http://scholarbank.nus.edu.sg/handle/10635/109899
ISSN: 00016314
DOI: 10.1111/j.1600-0404.2009.01263.x
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

21
checked on Feb 14, 2018

WEB OF SCIENCETM
Citations

21
checked on Feb 14, 2018

Page view(s)

40
checked on Feb 20, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.